Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?

Transfusion

Volumn 45, Issue 12, 2005, Pages 1965-1972

  Laperche, Syria ^a   Elghouzzi, Marie Hélène ^b   Morel, Pascal ^b   Asso Bonnet, Marianne ^b   Le Marrec, Nadine ^b   Girault, Annie ^b   Servant Delmas, Annabelle ^b   Bouchardeau, Françoise ^b   Deschaseaux, Marie ^b   Piquet, Yves ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; NUCLEIC ACID; NUCLEOCAPSID PROTEIN; BIOLOGICAL MARKER; CORE PROTEIN; VIRUS RNA;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; SEROCONVERSION; VIRUS DETECTION; VIRUS NUCLEOCAPSID; BLOOD; BLOOD BANK; GENETICS; IMMUNOASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BLOOD BANKS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOASSAY; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL CORE PROTEINS;

EID: 33644795532     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00648.x     Document Type: Article

References (41)

1. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
2. Busch M. Closing the windows on viral transmission by blood transfusion. In: Stramer SL, editor. Bethesda: American Association of Blood Banks; 2001. p. 33-54.
3. Courouce AM, Pillonel J. Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med 1996;335:1609-10.
4. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-8.
5. Kolk DP, Dockter J, Linnen J, et al. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol 2002;40:1761-6.
6. Pillonel J, Laperche S, Saura C, et al. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002;42:980-8.
7. Velati C, Romano L, Baruffi L, et al. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 2002;42:989-93.
8. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002;42:966-72.
9. Seed CR, Cheng A, Ismay SL, et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002;42:1365-72.
10. Assal A, Coste J, Barlet V, et al. Application of molecular biology to blood transfusion safety: the nucleic acid testing. Transfus Clin Biol 2003;10:217-26.
11. Roth WK, Weber M, Buhr S, et al. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002;42:862-8.
12. Mine H, Emura H, Miyamoto M, et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods 2003;112:145-51.
13. Eiras A, Sauleda S, Planelles D, et al. HCV screening in blood donations using RT-PCR in mini-pool: the experience in Spain after routine use for 2 years. Transfusion 2003;43:713-20.
14. Fang CT, Field SP, Busch MP, Heyns Adu P. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing. Vox Sang 2003;85:9-19.
15. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
16. Operskalski EA, Mosley JW, Tobler LH, et al. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003;43:1433-41.
17. Laperche S, Bouchardeau F, Maniez M, et al. Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral load. Vox Sang 2004;86:198.
18. Busch MP, Tobler LH, Gerlich WH, et al. Very low level viremia in HCV infectious unit missed by NAT. Transfusion 2003;43:1173-4.
19. Cano H, Candela MJ, Lozano ML, Vicente V. Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfus Med 2003;13:259-66.
20. Alvarez M, Planelles D, Vila E, et al. Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA. Vox Sang 2004;86:266-7.
21. Letowska M, Brojer E, Mikulska M, et al. Hepatitis C core antigen in Polish blood donors. Transfusion 2004;44:1067-71.
22. Raker CA, Tabor E, Okayama A, et al. HCV core antigen as an alternative to NAT to detect HCV viremia. Transfusion 2004;44:307-8.
23. Simmonds P, Kurtz J, Tedder R. The UK blood transfusion service: over a (patent) barrel. Lancet 2002;359:1713-4.
24. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004;86:28-40.
25. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-9.
26. Linnen JM, Gilker JM, Menez A, et al. Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription- mediated amplification. J Virol Methods 2002;102:139-55.
27. Lelie PN, van Drimmelen HA, Cuypers HT, et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002;42:527-36.
28. Coste J, Levayer T, Izopet J, et al. Acute HCV infection detected in a blood donor by NAT. Transfusion 2003;43:116-8.
29. Laperche S, Pillonel J, Herve P. HIV-1 and HCV infections among antibody-negative blood donors. N Engl J Med 2004;351:2232-5; author reply 5.
30. Sanz C, Tassies D, Costa J, et al. The first case of HCV infection detected before seroconversion in blood donors tested by HCV core antigen ELISA. Transfusion 2002;42:505-6.
31. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
32. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005;10 [Epub ahead of print].
33. Krajden M, Shivji R, Gunadasa K, et al. Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol 2004;42:4054-9.
34. Fabrizi F, Lunghi G, Aucella F, et al. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol 2005;43:414-20.
35. Dow BC, Munro H, Buchanan I, et al. Acute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening. Vox Sang 2004;86:15-20.
36. Laperche S, Le Marrec N, Simon N, et al. A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection. Transfusion 2003;43:958-62.
37. Courouce AM, Le Marrec N, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000;40:1198-202.
38. McLauchlan J, Lemberg MK, Hope G, Martoglio B. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002;21:3980-8.
39. Lai MM, Ware CF. Hepatitis C virus core protein: possible roles in viral pathogenesis. Curr Top Microbiol Immunol 2000;242:117-34.
40. Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19.
41. Ly TD, Laperche S, Brennan C, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004;122:185-94.